- Home
- UWMC vs GYRE Comparison
UWMC vs GYRE Comparison
Compare UWMC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- GYRE
- Stock Information
- Founded
- UWMC 1986
- GYRE 2002
- Country
- UWMC United States
- GYRE United States
- Employees
- UWMC N/A
- GYRE N/A
- Industry
- UWMC Finance: Consumer Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- GYRE Health Care
- Exchange
- UWMC Nasdaq
- GYRE Nasdaq
- Market Cap
- UWMC 825.8M
- GYRE 897.1M
- IPO Year
- UWMC N/A
- GYRE N/A
- Fundamental
- Price
- UWMC $4.25
- GYRE $8.00
- Analyst Decision
- UWMC Buy
- GYRE
- Analyst Count
- UWMC 8
- GYRE 0
- Target Price
- UWMC $6.46
- GYRE N/A
- AVG Volume (30 Days)
- UWMC 7.4M
- GYRE 204.0K
- Earning Date
- UWMC 08-05-2025
- GYRE 08-12-2025
- Dividend Yield
- UWMC 9.39%
- GYRE N/A
- EPS Growth
- UWMC N/A
- GYRE N/A
- EPS
- UWMC N/A
- GYRE 0.02
- Revenue
- UWMC $2,486,541,000.00
- GYRE $100,643,000.00
- Revenue This Year
- UWMC $11.32
- GYRE $21.04
- Revenue Next Year
- UWMC $22.84
- GYRE $89.64
- P/E Ratio
- UWMC N/A
- GYRE $100.02
- Revenue Growth
- UWMC 10.39
- GYRE N/A
- 52 Week Low
- UWMC $3.80
- GYRE $6.11
- 52 Week High
- UWMC $9.74
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- UWMC 52.67
- GYRE 48.18
- Support Level
- UWMC $3.98
- GYRE $7.49
- Resistance Level
- UWMC $4.40
- GYRE $7.80
- Average True Range (ATR)
- UWMC 0.16
- GYRE 0.51
- MACD
- UWMC 0.01
- GYRE 0.10
- Stochastic Oscillator
- UWMC 79.34
- GYRE 64.97
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.